Notice: This company has been marked as potentially delisted and may not be actively trading. Kinnate Biopharma (KNTE) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Kinetic Engineering Ltd (KNTE)July 24, 2024 | investing.comKNTE Kinnate Biopharma Inc.April 5, 2024 | seekingalpha.comTrading was temporarily halted for "KNTE" at 07:04 PM with a stated reason of "News pending."April 3, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Receives Average Recommendation of "Hold" from AnalystsShares of Kinnate Biopharma Inc. (NASDAQ:KNTE - Get Free Report) have received an average rating of "Hold" from the six research firms that are presently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and one has given a buy ratinApril 1, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Short Interest Down 43.6% in MarchKinnate Biopharma Inc. (NASDAQ:KNTE - Get Free Report) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 465,600 shares, a drop of 43.6% from the February 29th total of 825,000 shares. Currently, 2.0% of the company's shares are short sold. Based on an average daily volume of 381,000 shares, the days-to-cover ratio is currently 1.2 days.March 28, 2024 | marketbeat.comCitigroup Inc. Increases Position in Kinnate Biopharma Inc. (NASDAQ:KNTE)Citigroup Inc. raised its holdings in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) by 53,138.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 420,585 shares of the company's stock after buying an adMarch 22, 2024 | marketbeat.comKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 13, 2024 | businesswire.comKinnate Biopharma (KNTE) to Release Quarterly Earnings on WednesdayKinnate Biopharma (NASDAQ:KNTE) will be releasing earnings on Wednesday, March 13, Yahoo Finance reports.March 12, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Given Consensus Recommendation of "Hold" by BrokeragesKinnate Biopharma Inc. (NASDAQ:KNTE - Get Free Report) has been given an average rating of "Hold" by the six research firms that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the coMarch 7, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Stake Increased by Citigroup Inc.Citigroup Inc. increased its stake in Kinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) by 53,138.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 420,585 shares of the company's stock after buying an additiMarch 4, 2024 | marketbeat.comKinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratoriesMarch 1, 2024 | msn.comKinnate Biopharma Sells Exarafenib To Pierre Fabre Laboratories - Quick FactsMarch 1, 2024 | markets.businessinsider.comKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesMarch 1, 2024 | prnewswire.comKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesMarch 1, 2024 | globenewswire.comAcadian Asset Management LLC Raises Holdings in Kinnate Biopharma Inc. (NASDAQ:KNTE)Acadian Asset Management LLC grew its holdings in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) by 71.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 736,686 shares of the company's stFebruary 29, 2024 | marketbeat.comStifel Nicolaus Boosts Kinnate Biopharma (NASDAQ:KNTE) Price Target to $2.59Stifel Nicolaus increased their price target on Kinnate Biopharma from $1.50 to $2.59 and gave the company a "hold" rating in a research note on Monday.February 26, 2024 | marketbeat.comKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEFebruary 19, 2024 | businesswire.comKinnate Biopharma just downgraded at William Blair, here's whyFebruary 17, 2024 | realmoney.thestreet.comPrivate equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as wellFebruary 17, 2024 | finance.yahoo.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.February 16, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMAFebruary 16, 2024 | prnewswire.comKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to ShareholdersFebruary 16, 2024 | businesswire.comKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to ShareholdersFebruary 16, 2024 | businesswire.comKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareFebruary 16, 2024 | finance.yahoo.comKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareFebruary 16, 2024 | globenewswire.comTrading was temporarily halted for "KNTE" at 07:02 AM with a stated reason of "News pending."February 16, 2024 | marketbeat.comShort Interest in Kinnate Biopharma Inc. (NASDAQ:KNTE) Increases By 5.8%Kinnate Biopharma Inc. (NASDAQ:KNTE - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,100,000 shares, a growth of 5.8% from the January 15th total of 1,040,000 shares. Currently, 5.6% of the company's stock are sold short. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is currently 0.8 days.February 16, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Receives Average Recommendation of "Hold" from BrokeragesShares of Kinnate Biopharma Inc. (NASDAQ:KNTE - Get Free Report) have been given a consensus rating of "Hold" by the five brokerages that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and one has issued a buy recommendation oFebruary 11, 2024 | marketbeat.comLeerink Partnrs Weighs in on Kinnate Biopharma Inc.'s Q3 2024 Earnings (NASDAQ:KNTE)Kinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2024 earnings estimates for Kinnate Biopharma in a report released on Monday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn ($0.28) per share for the qFebruary 8, 2024 | marketbeat.comLeerink Partnrs Comments on Kinnate Biopharma Inc.'s Q1 2024 Earnings (NASDAQ:KNTE)Kinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Kinnate Biopharma in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company wFebruary 7, 2024 | marketbeat.comAnalysts Issue Forecasts for Kinnate Biopharma Inc.'s Q2 2024 Earnings (NASDAQ:KNTE)Kinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) - Investment analysts at Wedbush issued their Q2 2024 EPS estimates for Kinnate Biopharma in a report issued on Tuesday, January 16th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.28) per share for the quarter. WedbuJanuary 19, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Forecasted to Earn Q1 2024 Earnings of ($0.41) Per ShareKinnate Biopharma Inc. (NASDAQ:KNTE - Free Report) - Research analysts at Wedbush issued their Q1 2024 earnings per share (EPS) estimates for shares of Kinnate Biopharma in a report issued on Tuesday, January 16th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.41) per shaJanuary 18, 2024 | marketbeat.comWedbush Reiterates "Neutral" Rating for Kinnate Biopharma (NASDAQ:KNTE)Wedbush reissued a "neutral" rating and issued a $2.00 price objective on shares of Kinnate Biopharma in a research report on Wednesday.January 17, 2024 | marketbeat.comKinnate Biopharma Inc. (NASDAQ:KNTE) Sees Large Growth in Short InterestKinnate Biopharma Inc. (NASDAQ:KNTE - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 1,360,000 shares, a growth of 16.2% from the December 15th total of 1,170,000 shares. Based on an average trading volume of 1,290,000 shares, the short-interest ratio is presently 1.1 days. Currently, 6.9% of the shares of the stock are short sold.January 14, 2024 | marketbeat.comKinnate Biopharma: Righting The Ship, But Still Not The Right Time (Rating Upgrade)December 12, 2023 | seekingalpha.comKinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist InvestorsNovember 24, 2023 | finance.yahoo.comWhy is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?November 15, 2023 | msn.comOrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma IncNovember 15, 2023 | finance.yahoo.comKinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 9, 2023 | finance.yahoo.comInstrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)October 4, 2023 | theglobeandmail.comKinnate Biopharma (KNTE) Falls 40% in a Month: Here's WhyOctober 3, 2023 | finance.yahoo.comJefferies Maintains Kinnate Biopharma (KNTE) Buy RecommendationSeptember 20, 2023 | msn.comBay Area biotech company Kinnate to lay off 70% of workforceSeptember 19, 2023 | msn.comWedbush Downgrades Kinnate Biopharma (KNTE)September 19, 2023 | msn.comWhy Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?September 19, 2023 | msn.comPiper Sandler Downgrades Kinnate Biopharma (KNTE)September 19, 2023 | msn.comAnalysts Move To Sidelines For Cancer Player Kinnate Biopharma After RestructuringSeptember 19, 2023 | markets.businessinsider.comKinnate slashes workforce by 70%, shelves three drug programsSeptember 18, 2023 | msn.comKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringSeptember 18, 2023 | finance.yahoo.comTrading was temporarily halted for "KNTE" at 04:09 PM with a stated reason of "News pending."September 18, 2023 | marketbeat.com Get Kinnate Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. KNTE Media Mentions By Week KNTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNTE News Sentiment▼0.000.60▲Average Medical News Sentiment KNTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNTE Articles This Week▼01▲KNTE Articles Average Week Get Kinnate Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LianBio News PHAXIAM Therapeutics News Alpha Tau Medical News BriaCell Therapeutics News Fortress Biotech News GeoVax Labs News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNTE) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kinnate Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNTE Stock Alerts